Relay Therapeutics Shares Rise After Positive Trial Results and Analyst Upgrades
Relay Therapeutics (NASDAQ: RLAY) saw its stock rise nearly 8% on Wednesday following the release of positive Phase 2 trial results for zovegalisib, a treatment for vascular anomalies. The biotech company reported that 60% of patients responded to treatment at week 12 and noted favorable safety data. Analysts from Barclays and Citizens JMP raised their price targets while maintaining 'buy' ratings.
Topics: analyst upgrades Phase 2 clinical trials stock price movement zovegalisib